Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.54 |
| ▸ | TSHR | P16473 | 4/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 6/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | PDK1 | Q15118 | 3/20 | 0.50 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.50 |
| ▸ | PDK3 | Q15120 | 3/20 | 0.50 |
| ▸ | PDK4 | Q16654 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30447282 | 0.89 | PDK1 (0.62) | ALDH1A1KMT2AMEN1HSD17B10TSHR | |
| SCHEMBL22075949 | 0.89 | TSHR (0.56) | ALDH1A1KMT2AMEN1HSD17B10TSHR | |
| SCHEMBL30369541 | 0.87 | TSHR (0.56) | ALDH1A1KMT2AMEN1HSD17B10TSHR | |
| SCHEMBL22075942 | 0.87 | TSHR (0.56) | ALDH1A1KMT2AMEN1HSD17B10TSHR | |
| SCHEMBL24529070 | 0.85 | TSHR (0.53) | ALDH1A1KMT2AMEN1HSD17B10TSHR | |
| SCHEMBL23499607 | 0.81 | PARP1 (0.46) | ALDH1A1KMT2AMEN1HSD17B10TSHR | |
| SCHEMBL23499613 | 0.81 | ALDH1A1 (0.46) | ALDH1A1KMT2AMEN1HSD17B10TSHR | |
| SCHEMBL30144976 | 0.81 | PARP1 (0.46) | ALDH1A1KMT2AMEN1HSD17B10TSHR | |
| SCHEMBL30457883 | 0.79 | ALDH1A1 (0.52) | ALDH1A1KMT2AMEN1HSD17B10TSHR | |
| SCHEMBL30457882 | 0.79 | PDK1 (0.64) | ALDH1A1KMT2AMEN1HSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12551564-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20230190940-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230190940-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230190940-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| EP-4072591-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2022-10-19 | — | — | EP | disclosed |
| WO-2021119159-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-06-17 | — | — | WO | disclosed |
| WO-2021119159-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12551564-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | ALDH1A1 2901/4885KMT2A 594/4885MEN1 4729/4885 |
| US-20230190940-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885KMT2A 445/4885MEN1 4055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.